Corrigendum to: Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt- MAPK s pathway and NF-κB DNA-binding activity. (J Pineal Res., (2016), 60, (277-290), 10.1111/jpi.12308).;Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity

Journal of Pineal Research

Volumn 60, Issue 3, 2016, Pages 277-290

  Lin, Yung Wei ^a,b   Lee, Liang Ming ^b   Lee, Wei Jiunn ^b,c   Chu, Chih Ying ^a   Tan, Peng ^a   Yang, Yi Chieh ^d   Chen, Wei Yu ^b   Yang, Shun Fa ^e,f   Hsiao, Michael ^g   Chien, Ming Hsien ^a,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Akt; melatonin; metastasis; MMPs; NF B; renal cell carcinoma

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; MELATONIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN P52; STRESS ACTIVATED PROTEIN KINASE 1; SYNAPTOTAGMIN I; DNA; MMP9 PROTEIN, HUMAN; NFKB2 PROTEIN, HUMAN; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CELL MIGRATION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL METASTASIS; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSACTIVATION; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HL-60 CELL LINE; KIDNEY TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TRANSCRIPTION INITIATION;

ANIMALS; CARCINOMA, RENAL CELL; DNA, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; MELATONIN; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NF-KAPPA B P52 SUBUNIT; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960324653     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12382     Document Type: Erratum

References (60)

1. Comperat E, Camparo P,. Histological classification of malignant renal tumours at a time of major diagnostic and therapeutic changes. Diagn Interv Imaging 2012; 93: 221-231.
2. Jemal A, Siegel R, Xu J, et al., Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Maldazys JD, deKernion JB,. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376-379.
4. Zisman A, Pantuck AJ, Wieder J, et al., Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-4566.
5. Cohen HT, McGovern FJ,. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
6. Yang JC, Sherry RM, Steinberg SM, et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132.
7. Rini BI, Campbell SC, Escudier B,. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
8. Liotta LA, Kohn E,. Cancer invasion and metastases. JAMA 1990; 263: 1123-1126.
9. Engbring JA, Kleinman HK,. The basement membrane matrix in malignancy. J Pathol 2003; 200: 465-470.
10. Westermarck J, Kahari VM,. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792.
11. Yoon SO, Park SJ, Yun CH, et al., Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36: 128-137.
12. Miyata Y, Iwata T, Maruta S, et al., Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 2007; 52: 791-797.
13. Qiao ZK, Li YL, Lu HT, et al., Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J Surg Oncol 2013; 11: 1.
14. Cho NH, Shim HS, Rha SY, et al., Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 2003; 44: 560-566.
15. Sato A, Nagase H, Obinata D, et al., Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. Int J Oncol 2013; 43: 1441-1446.
16. Moore CS, Crocker SJ,. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180: 12-16.
17. Acuna-Castroviejo D, Escames G, Venegas C, et al., Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71: 2997-3025.
18. Manchester LC, Coto-Montes A, Boga JA, et al., Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res 2015; 59: 403-419.
19. Reiter RJ,. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37: 213-214.
20. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al., Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462-4481.
21. Bizzarri M, Proietti S, Cucina A, et al., Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013; 17: 1483-1496.
22. Cos S, Fernandez R, Guezmes A, et al., Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58: 4383-4390.
23. Ortiz-Lopez L, Morales-Mulia S, Ramirez-Rodriguez G, et al., ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. J Pineal Res 2009; 46: 15-21.
24. Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, et al., Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res 2014; 56: 20-30.
25. Wang J, Hao H, Yao L, et al., Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J Pineal Res 2012; 53: 180-187.
26. Collins A, Yuan L, Kiefer TL, et al., Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 2003; 189: 49-57.
27. Yang SF, Lee WJ, Tan P, et al., Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas. Oncotarget 2015; 6: 2736-2753.
28. Cos S, Sanchez-Barcelo EJ,. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21: 133-170.
29. Chen MW, Hua KT, Kao HJ, et al., H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010; 70: 7830-7840.
30. Overall CM, Lopez-Otin C,. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-672.
31. Lu H, Cao X, Zhang H, et al., Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumour Biol 2014; 35: 9807-9813.
32. Noh EM, Youn HJ, Jung SH, et al., Cordycepin inhibits TPA-induced matrix metalloproteinase-9 expression by suppressing the MAPK/AP-1 pathway in MCF-7 human breast cancer cells. Int J Mol Med 2010; 25: 255-260.
33. Huang CS, Fan YE, Lin CY, et al., Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. J Nutr Biochem 2007; 18: 449-456.
34. Bonizzi G, Karin M,. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288.
35. Kang MH, Oh SC, Lee HJ, et al., Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kappaB pathway, and MMP-9 expression. Exp Cell Res 2011; 317: 1746-1762.
36. Farriol M, Venereo Y, Orta X, et al., In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24.
37. Papazisis KT, Kouretas D, Geromichalos GD, et al., Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 1998; 25: 211-218.
38. Petranka J, Baldwin W, Biermann J, et al., The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26: 129-136.
39. Fan C, Pan Y, Yang Y, et al., HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways. J Pineal Res 2015; 59: 321-333.
40. Lissoni P, Barni S, Ardizzoia A, et al., Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992; 49: 336-339.
41. Wang YM, Jin BZ, Ai F, et al., The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012; 69: 1213-1220.
42. Otani N, Tsukamoto T, Saiki I, et al., In vitro invasive potential and type IV collagenolytic activity of human renal cell carcinoma cells derived from primary and metastatic lesions. J Urol 1993; 149: 1182-1185.
43. Chambers AF, MacDonald IC, Schmidt EE, et al., Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995; 14: 279-301.
44. Lein M, Jung K, Laube C, et al., Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000; 85: 801-804.
45. Taraboletti G, Garofalo A, Belotti D, et al., Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-298.
46. Yan C, Boyd DD,. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211: 19-26.
47. Sato H, Seiki M,. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993; 8: 395-405.
48. Takahra T, Smart DE, Oakley F, et al., Induction of myofibroblast MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by NF-kappaB, AP-1 and Sp1. Int J Biochem Cell Biol 2004; 36: 353-363.
49. Park JH, Jeong YJ, Park KK, et al., Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells 2010; 29: 209-215.
50. Huang SC, Ho CT, Lin-Shiau SY, et al., Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem Pharmacol 2005; 69: 221-232.
51. Robert I, Aussems M, Keutgens A, et al., Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes. Oncogene 2009; 28: 1626-1638.
52. Madrid LV, Mayo MW, Reuther JY, et al., Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276: 18934-18940.
53. Binion DG, Heidemann J, Li MS, et al., Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 2009; 297: G259-G268.
54. Chin YR, Toker A,. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009; 21: 470-476.
55. Sivaraman VS, Wang H, Nuovo GJ, et al., Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99: 1478-1483.
56. Rudra DS, Pal U, Maiti NC, et al., Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J Pineal Res 2013; 54: 398-405.
57. Vanecek J,. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78: 687-721.
58. Song Y, Chan CW, Brown GM, et al., Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997; 11: 93-100.
59. Leja-Szpak A, Jaworek J, Pierzchalski P, et al., Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
60. Carbajo-Pescador S, Garcia-Palomo A, Martin-Renedo J, et al., Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor. J Pineal Res 2011; 51: 463-471.